Association of compounded bevacizumab with postinjection endophthalmitis.

@article{Vanderbeek2015AssociationOC,
  title={Association of compounded bevacizumab with postinjection endophthalmitis.},
  author={Brian L. Vanderbeek and Sarah G Bonaffini and Liyuan Ma},
  journal={JAMA ophthalmology},
  year={2015},
  volume={133 10},
  pages={1159-64}
}
IMPORTANCE Current draft guidelines set forth by the US Food and Drug Administration for compounded or repackaged medications would greatly limit the availability and use of bevacizumab by ophthalmologists across the country. Little evidence beyond highly publicized case reports exists for or against the need for additional regulation of compounded bevacizumab. OBJECTIVE To determine whether the distribution of bevacizumab through compounding pharmacies increases the risk for endophthalmitis… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 26 times over the past 90 days. VIEW TWEETS